US Patent

US12016857 — Stable liquid vigabatrin pharmaceutical composition for oral dosage

Formulation · Assigned to Lm Manufacturing Ltd · Expires 2039-08-16 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable liquid pharmaceutical composition for oral dosage that includes an active ingredient, a buffering agent, and water.

USPTO Abstract

This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.

Drugs covered by this patent

Patent Metadata

Patent number
US12016857
Jurisdiction
US
Classification
Formulation
Expires
2039-08-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Lm Manufacturing Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.